MacroGenics, Inc.
MGNXNASDAQHealthcare● Active
$4.04
+$0.16(+4.12%)
Market Cap$256794924
P/E Ratio—
52W High$4.64
52W Low$1.185
MacroGenics, Inc. (MGNX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · MGNX · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.15B | $0.15B | $0.06B | $0.15B | $0.08B |
| Cost of Revenue | $0.04B | $0.01B | $0.01B | $0.01B | $0.00B |
| Gross Profit | $0.11B | $0.14B | $0.05B | $0.14B | $0.07B |
| Gross Margin %(computed) | 71.12% | 91.71% | 85.62% | 95.08% | 96.50% |
| Operating Expenses | |||||
| R&D Expenses | $0.14B | $0.18B | $0.17B | $0.21B | $0.21B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.18B | $0.25B | $0.22B | $0.26B | $0.28B |
| Operating Income | ($0.07B) | ($0.11B) | ($0.17B) | ($0.12B) | ($0.20B) |
| Operating Margin %(computed) | -48.72% | -74.54% | -294.17% | -80.94% | -268.09% |
| Interest Income | $0.00B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.08B) | ($0.07B) | ($0.01B) | ($0.12B) | ($0.20B) |
| Income Tax Expense | ($0.00B) | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.07B) | ($0.07B) | ($0.01B) | ($0.12B) | ($0.20B) |
| Net Margin %(computed) | -49.91% | -45.14% | -15.84% | -79.83% | -267.20% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.18 | $-1.07 | $-0.15 | $-1.95 | $-3.18 |
| Wtd Avg Shares | 0.06B | 0.06B | 0.06B | 0.06B | 0.06B |
| EBITDA | ($0.07B) | ($0.06B) | $0.00B | ($0.11B) | ($0.19B) |
| EBITDA Margin %(computed) | -43.93% | -38.67% | 3.53% | -71.92% | -252.31% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more MacroGenics, Inc. data
About MacroGenics, Inc. (MGNX) Income Statement
MacroGenics, Inc. (MGNX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, MGNX reported revenue of $0.15B, gross profit of $0.11B (gross margin 71.12%), and net income of ($0.07B) — a net profit margin of -49.91%.
Frequently asked questions
MGNX · 4 questionsMacroGenics, Inc. (MGNX) reported revenue of $0.15B for 2025, up 0.8% year-over-year.
MGNX revenueMGNX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09